Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
| chronic_progressive_external_ophthalmoplegia [2026/09/08 12:37] – [Genetics] Scott Larson | chronic_progressive_external_ophthalmoplegia [2026/09/08 12:40] (current) – Scott Larson | ||
|---|---|---|---|
| Line 20: | Line 20: | ||
| ===== Diagnostic Evaluation ===== | ===== Diagnostic Evaluation ===== | ||
| - | * **Clinical eye and systemic exam** — motility, lids, pupils, dilated fundus, cardiac review | + | * **Clinical eye and systemic exam** — motility, lids, pupils, dilated fundus, cardiac review. |
| - | * **Screening labs** — resting/ | + | * **Screening labs** — resting/ |
| - | * **Exclude mimics** — myasthenia gravis (AChR/MuSK antibodies), | + | * **Exclude mimics** — myasthenia gravis (AChR/MuSK antibodies), |
| - | * **Muscle biopsy** (most accurate single test) — **ragged-red fibers** (Gomori trichrome) and **COX-negative / SDH-hyperintense fibers**; also enables respiratory-chain enzyme assays | + | * **Muscle biopsy** (most accurate single test) — **ragged-red fibers** (Gomori trichrome) and **COX-negative / SDH-hyperintense fibers**; also enables respiratory-chain enzyme assays. |
| - | * **Genetic testing** — whole mtDNA sequencing plus long-range PCR for deletions; **muscle is the optimal tissue**; nuclear gene panels when multiple deletions/ | + | * **Genetic testing** — whole mtDNA sequencing plus long-range PCR for deletions; **muscle is the optimal tissue**; nuclear gene panels when multiple deletions/ |
| ===== Key Points ===== | ===== Key Points ===== | ||
| * No blood test is confirmatory; | * No blood test is confirmatory; | ||
| - | * A **negative blood mtDNA test does not rule out** the disease — proceed to muscle if suspicion is high ((li)). | + | * A **negative blood mtDNA test does not rule out** the disease — proceed to muscle if suspicion is high. |
| - | * Screen for and monitor **cardiac conduction disease**, a source of preventable morbidity/ | + | * Screen for and monitor **cardiac conduction disease**, a source of preventable morbidity/ |
| ====Compare CPEO with Congenital Fibrosis of EOM (CFEOM)==== | ====Compare CPEO with Congenital Fibrosis of EOM (CFEOM)==== | ||